Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Ah-See ML"'
Autor:
Li SP, Padhani AR, Taylor NJ, Beresford MJ, Ah-See ML, Stirling JJ, d'Arcy JA, Collins DJ, Makris A, Li, Sonia P, Padhani, Anwar R, Taylor, N Jane, Beresford, Mark J, Ah-See, Mei-Lin W, Stirling, J James, d'Arcy, James A, Collins, David J, Makris, Andreas
Publikováno v:
European Radiology; Jul2011, Vol. 21 Issue 7, p1364-1373, 10p
Autor:
Lord, S, Cheng, WC, Liu, D, Gaude, E, Haider, S, Patel, N, Teoh, E, Gleeson, F, Mcgowan, D, Thompson, A, Ah-See, ML, Snell, C, Ayers, L, Karpe, F, Pollak, M, Frezza, C, Fenwick, J, Buffa, F, Harris, A
Publikováno v:
Publons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::32b4506829fe78b6f19aa68df6d55f6f
https://publons.com/publon/28514758/
https://publons.com/publon/28514758/
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Drew Y; Department of Medical Oncology, BC Cancer - Vancouver and University of British Columbia, Vancouver, British Columbia, Canada., Kim JW; Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Republic of Korea., Penson RT; Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts., O'Malley DM; Division of Gynecology Oncology, James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio., Parkinson C; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom., Roxburgh P; Medical Oncology, Beatson West of Scotland Cancer Centre, and School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom., Plummer R; Translational and Clinical Research Institute, Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, and Newcastle University, Newcastle upon Tyne, United Kingdom., Im SA; Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea., Imbimbo M; Immuno-oncology Service, Department of Oncology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland., Ferguson M; Department of Oncology, NHS Tayside, Ninewells Hospital, Dundee, United Kingdom., Rosengarten O; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel., Steeghs N; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Kim MH; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Gal-Yam E; Chaim Sheba Medical Center, Tel HaShomer, Israel., Tsoref D; Rabin Medical Center-Beilinson Campus, Petach Tikva and Tel-Aviv University, Tel-Aviv, Israel., Kim JH; Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea., You B; Service d'Oncologie Médicale, CITOHL, EPSLYON, Institut de Cancérologie des Hospices Civils de Lyon, IC-HCL, Université Claude Bernard Lyon 1, Lyon, France., De Jonge M; Department of Medical Oncology, Erasmus Medisch Centrum, Rotterdam, the Netherlands., Lalisang R; Division of Medical Oncology, Department of Internal Medicine, GROW - School of Oncology and Reproduction, Maastricht UMC+ Comprehensive Cancer Center, Maastricht University Medical Centre, Maastricht, the Netherlands., Gort E; Department of Medical Oncology, UMC Utrecht, Utrecht, the Netherlands., Bastian S; Medical Oncology and Haematology, Kantonsspital Graubuenden, Chur, Switzerland., Meyer K; Late Development Oncology, Oncology R&D, AstraZeneca, Gaithersburg, Maryland., Feeney L; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Baker N; Oncology Biometrics, AstraZeneca, Cambridge, United Kingdom., Ah-See ML; Late-stage Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Domchek SM; Basser Center for BRCA, University of Pennsylvania, Philadelphia, Pennsylvania., Banerjee S; Gynaecology Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Jan 05; Vol. 30 (1), pp. 50-62.
Autor:
Någård M; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, AstraZeneca, One MedImmune Way, Gaithersburg, MD, 20878, USA. Mats.Nagard@astrazeneca.com., Ah-See ML; Late-Stage Development, Oncology R&D, AstraZeneca, Cambridge, UK., Strauss J; Mary Crowley Cancer Research Center, Dallas, TX, USA., Wise-Draper T; University of Cincinnati Cancer Center, Cincinnati, OH, USA., Safran HP; Rhode Island Hospital, Lifespan Cancer Institute, Providence, RI, USA., Nadeau L; Beaumont Cancer Center, Royal Oak, MI, USA., Edenfield WJ; Institute for Translational Oncology Research, Greenville, SC, USA., Lewis LD; The Dartmouth Cancer Center and Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA., Ottesen LH; Late-Stage Development, Oncology R&D, AstraZeneca, Cambridge, UK., Li Y; Integrated Bioanalysis, Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Boston, MA, USA., Mugundu GM; Clinical Pharmacology and Quantitative Pharmacology, R&D Clinical Pharmacology and Safety Sciences, AstraZeneca, Waltham, MA, USA.
Publikováno v:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2023 Sep; Vol. 92 (3), pp. 193-203. Date of Electronic Publication: 2023 Jul 02.
Autor:
Någård M; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, AstraZeneca, One MedImmune Way, Gaithersburg, MD, 20878, USA. Mats.Nagard@astrazeneca.com., Ah-See ML; Late Stage Development, Oncology R&D, AstraZeneca, Cambridge, UK., Strauss J; Mary Crowley Cancer Research Center, Dallas, TX, USA., Wise-Draper T; University of Cincinnati Cancer Center, Cincinnati, OH, USA., Safran HP; Rhode Island Hospital, Lifespan Cancer Institute, Providence, RI, USA., Nadeau L; Beaumont Cancer Center, Royal Oak, MI, USA., Edenfield WJ; Institute for Translational Oncology Research, Greenville, SC, USA., Lewis LD; The Dartmouth Cancer Center and Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA., Rekić D; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, AstraZeneca, Gothenburg, Sweden., Dota C; Cardiovascular Safety Center of Excellence, CMO, Oncology R&D, AstraZeneca, Gothenburg, Sweden., Ottesen LH; Late Stage Development, Oncology R&D, AstraZeneca, Cambridge, UK., Li Y; Integrated Bioanalysis, Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Boston, MA, USA., Mugundu GM; Clinical Pharmacology and Quantitative Pharmacology, R&D Clinical Pharmacology and Safety Sciences Clinical Pharmacology, Waltham, MA, USA.
Publikováno v:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2023 Aug; Vol. 92 (2), pp. 141-150. Date of Electronic Publication: 2023 Jun 27.
Autor:
Krebs MG; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, UK. Electronic address: matthew.krebs@manchester.ac.uk., Delord JP; Department of Medical Oncology, IUCT-Oncopole, Toulouse, France., Jeffry Evans TR; University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK., De Jonge M; Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Kim SW; Asan Medical Center, Seoul, South Korea., Meurer M; Centre d'Essais Précoces en Cancérologie de Marseille, Assistance Publique-Hôpitaux de Marseille, Marseille, France., Postel-Vinay S; Department of Drug Development, Gustave Roussy Cancer Campus, Villejuif, France., Lee JS; Seoul National University College of Medicine, Bundang Hospital, Seoul, South Korea., Angell HK; AstraZeneca, Cambridge, UK., Rocher-Ros V; AstraZeneca, Cambridge, UK., Meyer K; AstraZeneca, Gaithersburg, MD, USA., Ah-See ML; AstraZeneca, Cambridge, UK., Herbolsheimer P; AstraZeneca, Gaithersburg, MD, USA., Lai Z; AstraZeneca, Gaithersburg, MD, USA., Nunes A; AstraZeneca, Gaithersburg, MD, USA., Domchek SM; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Publikováno v:
Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2023 Jun; Vol. 180, pp. 107216. Date of Electronic Publication: 2023 Apr 24.
Autor:
DiSilvestro P; Program in Women's Oncology, Women & Infants Hospital, Providence, RI., Banerjee S; The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom., Colombo N; University of Milan-Bicocca and Istituto Europeo di Oncologia IRCCS, Milan, Italy., Scambia G; Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy., Kim BG; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Oaknin A; Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Friedlander M; University of New South Wales Clinical School, Prince of Wales Hospital, Randwick, New South Wales, Australia., Lisyanskaya A; St Petersburg City Oncology Dispensary, St Petersburg, Russia., Floquet A; Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France.; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Paris, France., Leary A; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Paris, France.; Institut Gustave-Roussy, Villejuif, France., Sonke GS; The Netherlands Cancer Institute, Amsterdam, the Netherlands., Gourley C; Cancer Research UK Scotland Center, University of Edinburgh, Edinburgh, United Kingdom., Oza A; Princess Margaret Cancer Center, Toronto, ON, Canada., González-Martín A; Clínica Universidad de Navarra, Madrid, Spain.; Program In Solid Tumours, CIMA, Pamplona, Spain., Aghajanian C; Memorial Sloan Kettering Cancer Center, New York, NY., Bradley W; Froedtert and the Medical College of Wisconsin, Milwaukee, WI., Mathews C; Program in Women's Oncology, Women & Infants Hospital, Providence, RI., Liu J; Dana-Farber Cancer Institute, Boston, MA., McNamara J; Biostatistics, Oncology Biometrics, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Lowe ES; Global Medicines Development, Oncology, AstraZeneca, Gaithersburg, MD., Ah-See ML; Oncology R&D, Late-stage Development, AstraZeneca, Cambridge, United Kingdom., Moore KN; Stephenson Oklahoma Cancer Center, Oklahoma City, OK.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Jan 20; Vol. 41 (3), pp. 609-617. Date of Electronic Publication: 2022 Sep 09.
Autor:
Kosmin M; From the Department of Oncology, University College London NHS Foundation Trust, 250 Euston Road, London NW1 2PG, England (M.K.); Paul Strickland Scanner Centre (A.R.P., A.G.) and Breast Cancer Research Unit (P.O., S.S., D.M., A. Makris), Mount Vernon Cancer Centre, Northwood, Middlesex, England; Department of Clinical Oncology, the Christie NHS Foundation Trust, Manchester, England (D.W.); Astra Zeneca UK Limited, Cambridge, England (M.L.A.); the Royal Marsden Hospital, Sutton, Surrey, England (J.N., D.M.K.); and Warwick Clinical Trials Unit, University of Warwick, Coventry, England (A. Marshall, J.D.)., Padhani AR; From the Department of Oncology, University College London NHS Foundation Trust, 250 Euston Road, London NW1 2PG, England (M.K.); Paul Strickland Scanner Centre (A.R.P., A.G.) and Breast Cancer Research Unit (P.O., S.S., D.M., A. Makris), Mount Vernon Cancer Centre, Northwood, Middlesex, England; Department of Clinical Oncology, the Christie NHS Foundation Trust, Manchester, England (D.W.); Astra Zeneca UK Limited, Cambridge, England (M.L.A.); the Royal Marsden Hospital, Sutton, Surrey, England (J.N., D.M.K.); and Warwick Clinical Trials Unit, University of Warwick, Coventry, England (A. Marshall, J.D.)., Gogbashian A; From the Department of Oncology, University College London NHS Foundation Trust, 250 Euston Road, London NW1 2PG, England (M.K.); Paul Strickland Scanner Centre (A.R.P., A.G.) and Breast Cancer Research Unit (P.O., S.S., D.M., A. Makris), Mount Vernon Cancer Centre, Northwood, Middlesex, England; Department of Clinical Oncology, the Christie NHS Foundation Trust, Manchester, England (D.W.); Astra Zeneca UK Limited, Cambridge, England (M.L.A.); the Royal Marsden Hospital, Sutton, Surrey, England (J.N., D.M.K.); and Warwick Clinical Trials Unit, University of Warwick, Coventry, England (A. Marshall, J.D.)., Woolf D; From the Department of Oncology, University College London NHS Foundation Trust, 250 Euston Road, London NW1 2PG, England (M.K.); Paul Strickland Scanner Centre (A.R.P., A.G.) and Breast Cancer Research Unit (P.O., S.S., D.M., A. Makris), Mount Vernon Cancer Centre, Northwood, Middlesex, England; Department of Clinical Oncology, the Christie NHS Foundation Trust, Manchester, England (D.W.); Astra Zeneca UK Limited, Cambridge, England (M.L.A.); the Royal Marsden Hospital, Sutton, Surrey, England (J.N., D.M.K.); and Warwick Clinical Trials Unit, University of Warwick, Coventry, England (A. Marshall, J.D.)., Ah-See ML; From the Department of Oncology, University College London NHS Foundation Trust, 250 Euston Road, London NW1 2PG, England (M.K.); Paul Strickland Scanner Centre (A.R.P., A.G.) and Breast Cancer Research Unit (P.O., S.S., D.M., A. Makris), Mount Vernon Cancer Centre, Northwood, Middlesex, England; Department of Clinical Oncology, the Christie NHS Foundation Trust, Manchester, England (D.W.); Astra Zeneca UK Limited, Cambridge, England (M.L.A.); the Royal Marsden Hospital, Sutton, Surrey, England (J.N., D.M.K.); and Warwick Clinical Trials Unit, University of Warwick, Coventry, England (A. Marshall, J.D.)., Ostler P; From the Department of Oncology, University College London NHS Foundation Trust, 250 Euston Road, London NW1 2PG, England (M.K.); Paul Strickland Scanner Centre (A.R.P., A.G.) and Breast Cancer Research Unit (P.O., S.S., D.M., A. Makris), Mount Vernon Cancer Centre, Northwood, Middlesex, England; Department of Clinical Oncology, the Christie NHS Foundation Trust, Manchester, England (D.W.); Astra Zeneca UK Limited, Cambridge, England (M.L.A.); the Royal Marsden Hospital, Sutton, Surrey, England (J.N., D.M.K.); and Warwick Clinical Trials Unit, University of Warwick, Coventry, England (A. Marshall, J.D.)., Sutherland S; From the Department of Oncology, University College London NHS Foundation Trust, 250 Euston Road, London NW1 2PG, England (M.K.); Paul Strickland Scanner Centre (A.R.P., A.G.) and Breast Cancer Research Unit (P.O., S.S., D.M., A. Makris), Mount Vernon Cancer Centre, Northwood, Middlesex, England; Department of Clinical Oncology, the Christie NHS Foundation Trust, Manchester, England (D.W.); Astra Zeneca UK Limited, Cambridge, England (M.L.A.); the Royal Marsden Hospital, Sutton, Surrey, England (J.N., D.M.K.); and Warwick Clinical Trials Unit, University of Warwick, Coventry, England (A. Marshall, J.D.)., Miles D; From the Department of Oncology, University College London NHS Foundation Trust, 250 Euston Road, London NW1 2PG, England (M.K.); Paul Strickland Scanner Centre (A.R.P., A.G.) and Breast Cancer Research Unit (P.O., S.S., D.M., A. Makris), Mount Vernon Cancer Centre, Northwood, Middlesex, England; Department of Clinical Oncology, the Christie NHS Foundation Trust, Manchester, England (D.W.); Astra Zeneca UK Limited, Cambridge, England (M.L.A.); the Royal Marsden Hospital, Sutton, Surrey, England (J.N., D.M.K.); and Warwick Clinical Trials Unit, University of Warwick, Coventry, England (A. Marshall, J.D.)., Noble J; From the Department of Oncology, University College London NHS Foundation Trust, 250 Euston Road, London NW1 2PG, England (M.K.); Paul Strickland Scanner Centre (A.R.P., A.G.) and Breast Cancer Research Unit (P.O., S.S., D.M., A. Makris), Mount Vernon Cancer Centre, Northwood, Middlesex, England; Department of Clinical Oncology, the Christie NHS Foundation Trust, Manchester, England (D.W.); Astra Zeneca UK Limited, Cambridge, England (M.L.A.); the Royal Marsden Hospital, Sutton, Surrey, England (J.N., D.M.K.); and Warwick Clinical Trials Unit, University of Warwick, Coventry, England (A. Marshall, J.D.)., Koh DM; From the Department of Oncology, University College London NHS Foundation Trust, 250 Euston Road, London NW1 2PG, England (M.K.); Paul Strickland Scanner Centre (A.R.P., A.G.) and Breast Cancer Research Unit (P.O., S.S., D.M., A. Makris), Mount Vernon Cancer Centre, Northwood, Middlesex, England; Department of Clinical Oncology, the Christie NHS Foundation Trust, Manchester, England (D.W.); Astra Zeneca UK Limited, Cambridge, England (M.L.A.); the Royal Marsden Hospital, Sutton, Surrey, England (J.N., D.M.K.); and Warwick Clinical Trials Unit, University of Warwick, Coventry, England (A. Marshall, J.D.)., Marshall A; From the Department of Oncology, University College London NHS Foundation Trust, 250 Euston Road, London NW1 2PG, England (M.K.); Paul Strickland Scanner Centre (A.R.P., A.G.) and Breast Cancer Research Unit (P.O., S.S., D.M., A. Makris), Mount Vernon Cancer Centre, Northwood, Middlesex, England; Department of Clinical Oncology, the Christie NHS Foundation Trust, Manchester, England (D.W.); Astra Zeneca UK Limited, Cambridge, England (M.L.A.); the Royal Marsden Hospital, Sutton, Surrey, England (J.N., D.M.K.); and Warwick Clinical Trials Unit, University of Warwick, Coventry, England (A. Marshall, J.D.)., Dunn J; From the Department of Oncology, University College London NHS Foundation Trust, 250 Euston Road, London NW1 2PG, England (M.K.); Paul Strickland Scanner Centre (A.R.P., A.G.) and Breast Cancer Research Unit (P.O., S.S., D.M., A. Makris), Mount Vernon Cancer Centre, Northwood, Middlesex, England; Department of Clinical Oncology, the Christie NHS Foundation Trust, Manchester, England (D.W.); Astra Zeneca UK Limited, Cambridge, England (M.L.A.); the Royal Marsden Hospital, Sutton, Surrey, England (J.N., D.M.K.); and Warwick Clinical Trials Unit, University of Warwick, Coventry, England (A. Marshall, J.D.)., Makris A; From the Department of Oncology, University College London NHS Foundation Trust, 250 Euston Road, London NW1 2PG, England (M.K.); Paul Strickland Scanner Centre (A.R.P., A.G.) and Breast Cancer Research Unit (P.O., S.S., D.M., A. Makris), Mount Vernon Cancer Centre, Northwood, Middlesex, England; Department of Clinical Oncology, the Christie NHS Foundation Trust, Manchester, England (D.W.); Astra Zeneca UK Limited, Cambridge, England (M.L.A.); the Royal Marsden Hospital, Sutton, Surrey, England (J.N., D.M.K.); and Warwick Clinical Trials Unit, University of Warwick, Coventry, England (A. Marshall, J.D.).
Publikováno v:
Radiology [Radiology] 2020 Dec; Vol. 297 (3), pp. 622-629. Date of Electronic Publication: 2020 Oct 20.
Autor:
Någård M; Clinical Pharmacology and Quantitative Pharmacology, R&D Clinical Pharmacology and Safety Sciences, AstraZeneca, Gaithersburg, MD, USA., Ah-See ML; Late Stage Development, Oncology R&D, AstraZeneca, Cambridge, UK., So K; Late Stage Development, Oncology R&D, AstraZeneca, Cambridge, UK., Vermunt M; The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Thistlethwaite F; The Christie NHS Foundation Trust and University of Manchester, Manchester, UK., Labots M; Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands., Roxburgh P; Beaston West of Scotland Cancer Centre and University of Glasgow, Glasgow, UK., Ravaud A; Bordeaux University Hospital, Bordeaux, France., Campone M; ICO - Site René, Saint Herblain, France., Valkenburg-van Iersel L; Maastricht University Medical Centre, Maastricht, The Netherlands., Ottesen L; Late Stage Development, Oncology R&D, AstraZeneca, Cambridge, UK., Li Y; Clinical Pharmacology Biologics and Bioanalysis, Clinical Pharmacology and Safety Science, BioPharmaceuticals R&D, AstraZeneca, Boston, MA, USA., Mugundu G; Clinical Pharmacology and Quantitative Pharmacology, R&D Clinical Pharmacology and Safety Sciences, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA. ganesh.mugundu@astrazeneca.com.
Publikováno v:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2020 Jul; Vol. 86 (1), pp. 97-108. Date of Electronic Publication: 2020 Jun 16.